

11/13/00  
JC613 U.S. PTO

11-14-00

A

**UTILITY PATENT APPLICATION TRANSMITTAL**  
(Only for new nonprovisional applications under 37 CFR 1.53(b))

JC688 U.S. PTO  
09/711648

11/13/00

Docket No. : 37646/KMO/W112  
Inventor(s) : Dean M. Ponzi, Asher Holzer, and Shlomo Ben-Haim  
Title : INJECTION CATHETER WITH NEEDLE ELECTRODE  
Express Mail Label No. : EL387002345US

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

Date: November 13, 2000

1. ☐ **FEE TRANSMITTAL FORM** (*Submit an original, and a duplicate for fee processing*).
2. **IF A CONTINUING APPLICATION**  
☒ This application is a Continuation-in-Part of patent application No. 09/280,202, filed March 29, 1999, which claims priority of U.S. Provisional Patent Application Nos. 60/088,019, filed June 4, 1998 and 60/088,984, filed on June 11, 1998.  
  
Prior application information: Examiner Kevin C. Sirmons; Group Art Unit: 3763  
  
☐ This application claims priority pursuant to 35 U.S.C. §119(e) and 37 CFR §1.78(a)(4), to provisional Application No. , filed  
  
3. **APPLICATION COMPRISED OF**  
  
**Specification**  
☐ 23 Specification, claims and Abstract (total pages)  
  
**Drawings**  
☐ 11 Sheets of drawing(s) (FIGS. 1 to 8)  
  
**Declaration and Power of Attorney**  
☐ Newly executed  
☒ Unexecuted declaration  
☐ Copy from a prior application (37 CFR 1.63(d))(for continuation and divisional)  
  
4. ☐ **Microfiche Computer Program** (*Appendix*)  
  
5. ☐ **Nucleotide and/or Amino Acid Sequence Submission** (*if applicable, all necessary*)  
☐ Computer Readable Copy  
☐ Paper Copy (identical to computer copy)  
☐ Statement verifying identity of above copies  
  
6. **APPLICANT(S) STATUS UNDER 37 CFR § 1.27**  
☐ Applicant(s) and any others associated with it/them under § 1.27(a) are a SMALL ENTITY

---

---

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Only for new nonprovisional applications under 37 CFR 1.53(b))**

---

---

Docket No.: 37646/KMO/W112

---

---

**7. ALSO ENCLOSED ARE**

- ☐ Preliminary Amendment
- ☐ A Petition for Extension of Time for the parent application and the required fee are enclosed as separate papers
- ☐ An Assignment of the invention with the Recordation Cover Sheet and the recordation fee are enclosed as separate papers
- ☐ This application is owned by pursuant to an Assignment recorded at Reel , Frame
- ☒ Information Disclosure Statement (IDS)/PTO-1449
- ☒ Copies of IDS Citations
- ☐ Certified copy of Priority Document(s) (*if foreign priority is claimed*)
- ☐ English Translation Document (*if applicable*)
- ☒ Return Receipt Postcard (MPEP 503) (should be specifically itemized).
- ☐ Other


**8. CORRESPONDENCE ADDRESS**

**CHRISTIE, PARKER & HALE, LLP, P.O. BOX 7068, PASADENA, CA 91109-7068**  
**Customer Number: 23363**

Respectfully submitted,

CHRISTIE, PARKER & HALE, LLP

By

  
Kathleen M. Olster  
Reg. No. 42,052  
626/795-9900

KMO/nml

**FEE TRANSMITTAL  
UTILITY PATENT APPLICATION**

**DATE: November 13, 2000**

Docket No. :	37646/KMO/W112
Inventor(s) :	Dean M. Ponzi, Asher Holzer, and Shlomo Ben-Haim
Title :	INJECTION CATHETER WITH NEEDLE ELECTRODE

**FEE DETERMINATION**

CLAIMS AS FILED					
	NUMBER FILED	NUMBER EXTRA	SMALL ENTITY RATE	LARGE ENTITY RATE	FEE
TOTAL CLAIMS	20 – 20	0	0 x \$9.00	0 x \$18.00	-0-
INDEPENDENT CLAIMS	2 – 3	0	0 x \$40.00	0 x \$80.00	-0-
MULTIPLE-DEPENDENT CLAIMS FEE			\$135.00	\$270.00	-0-
BASIC FEE			\$355.00	\$710.00	\$710.00
TOTAL FILING FEE					\$710.00
List Independent Claims: 1 and 9					

**METHOD OF PAYMENT**

☒ Payment Enclosed: Check for \$710.00

☒ The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 and 1.17 which may be required during the **entire pendency** of the application to Deposit Account No. 03-1728. Please show our docket number with any charge or credit to our Deposit Account. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,

CHRISTIE, PARKER & HALE, LLP

By 

Kathleen M. Olster  
Reg. No. 42,052  
626/795-9900

## INJECTION CATHETER WITH NEEDLE ELECTRODE

### CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Patent Application No. 09/280,202, filed March 29, 1999, which claims the benefit of U.S. Provisional Patent Application Nos. 60/088,019, filed on June 4, 1998, and 60/088,984, filed on June 11, 1998, the entire disclosures of which are incorporated herein by reference.

### FIELD OF THE INVENTION

This invention relates to a catheter for infusing therapeutic or diagnostic agents into the tissue of organs having an injection needle that also serves as an electrode for mapping and/or ablation.

### BACKGROUND OF THE INVENTION

Targeted delivery of therapeutic or diagnostic agents, such as occurs in gene therapy, is very desirable but often presents a difficult challenge. A potential benefit of targeted delivery is that there is an increased efficiency obtained by the precise placement of the therapeutic or diagnostic agent. There are several problems to his procedure which must be overcome in order to obtain satisfactory results from such therapy, such as the problems of obtaining access to the delivery site, transporting the therapeutic or diagnostic agent to the desired site, injecting the agent at the proper depth within the organ tissue, steering the distal end of the catheter to a desired location within the organ prior to infusing the agent, and positioning the distal tip of the catheter at precisely the same location where prior measurements have indicated that the drug should be infused. It is also important to for a physician to be able to monitor the position of the infusion needle with respect to the wall of the organ. In the case of an organ, such as the heart, in which the walls are in constant motion, the activity of positioning and monitoring the position of the distal tip of the catheter, or infusion needle, becomes especially difficult.

U.S. Patent No. 3,598,119 discloses a medical device for injecting drugs in which the injection needle is guided through an inner lumen of a catheter for insertion of the needle under skin tissue. A bladder at the distal end of the catheter may be inflated through another lumen for holding the point of the needle point in a fixed position beneath the skin.

U.S. Patent No. 4,578,061 discloses a catheter for injecting a liquid into a vein, or artery, through an injection needle which is longitudinally movable beyond the distal end of the catheter.

A dual chamber system is utilized within the catheter tip to provide for movement of a plunger to extend the injection needle and also to allow for a plunger to be used to apply a predetermined dose of medication through the injection needle.

U.S. Patent No. 4,578,061 discloses an injection catheter having a longitudinal movable needle which may be moved through a lumen in order to extend out of the side wall of the catheter for injecting a liquid into a blood vessel. The needle is normally retracted into the device so that the needle will not penetrate tissue as the device is moved through a body duct. Thereafter, the needle is moved out of the side of the catheter into a vessel wall in order to infuse a liquid into the wall of a vessel.

U.S. Patent No. 5,244,460 is directed toward a method for improving blood flow to the heart. More particularly this patent is directed toward a medical procedure for improving the growth of cardiac blood vessels by inserting a catheter into a coronary artery and injecting into the heart a blood vessel growth promoting peptide through an injection port of the catheter.

U.S. Patent No. 5,419,777 is directed toward a catheter for injection of a fluid into body cavities such as coronary vessels and arteries. This patent, as is the case with the '061 patent, illustrates the use of an injection needle which protrudes laterally through the side walls of the distal tip of the catheter. In the case of drug injections to be made into coronary vessels and arteries, it is very desirable to have the needles extend out of the side walls of the catheter and at an acute angle to the walls of the vessel in order to penetrate the walls of the vessel for injection of the agent.

U.S. Patent 5,431,168, assigned to the same assignee as the present patent application, is directed toward a steerable catheter which includes a puller wire for controlling the distal end of the catheter from a control handle which is mounted on the proximal end of the catheter.

Copending U.S. Patent Application Serial No. 09/019,453, entitled "Intracardiac Drug Delivery," assigned to an affiliated company of the assignee of this application, discloses an injection catheter system for infusing a diagnostic or therapeutic agent into the wall of an organ which includes an electromagnetic sensor disposed within the distal tip of the catheter for providing very precise location information for the distal tip of the catheter. The subject matter of this copending patent application is incorporated by reference into the subject patent application.

# SUMMARY OF THE INVENTION

This present invention is directed to a catheter for infusing therapeutic or diagnostic agents into the tissue of organs wherein the injection needle can also be used for mapping and ablation. In one embodiment, the injection catheter comprises a catheter body comprising a flexible tubing having proximal and distal ends and at least one lumen therethrough. A tip section comprising a flexible tubing having proximal and distal ends is mounted at the distal end of the catheter body. It is understood that the tip section and catheter body can be two separate components fixedly attached together or a single integral tubing wherein the tip section is the distal end of the tubing on which is mounted, for example, the tip electrode and ring electrodes.

A needle control handle is provided at the proximal end of the catheter body. An injection needle extends through the tip section, catheter body, and needle control handle and has a proximal end attached to the needle control handle and a distal end within the tip section. The injection needle is longitudinally slidable within the tip section so that its distal end can extend beyond the distal end of the tip section upon suitable manipulation of the needle control handle. An electrode lead wire is electrically connected to the injection needle and to a suitable monitoring apparatus or to a source of ablation energy.

In another embodiment, the invention is directed to a method for introducing a therapeutic or diagnostic agent into heart tissue of a patient. The method comprises introducing the distal end of a catheter as described above into the patient's heart. The injection needle is extended beyond the distal end of the tip section, and it is determined whether the injection needle has penetrated the heart tissue, preferably by measuring the impedance across the distal end of the injection needle. If the injection needle has penetrated the tissue, the therapeutic or diagnostic agent is injected into the heart tissue with the injection needle. Otherwise, the physician can reposition the distal end of the catheter and again attempt to penetrate the heart tissue.

In another embodiment, the invention is directed to a catheter comprising a catheter body, tip section and needle control handle as described above. An injection needle extends through the tip section, catheter body, and needle control handle and has a proximal end attached to the needle control handle and a distal end within the tip section. The injection needle is longitudinally slidable within the tip section so that its distal end can extend beyond the distal end of the tip section upon suitable manipulation of the needle control handle. An electrode is mounted on the injection needle near the distal end of the injection needle and electrically isolated from the injection needle. An electrode lead wire is electrically connected to the electrode and to a suitable monitoring apparatus or to a source of ablation energy.

In another embodiment, the invention is directed to a method for introducing a therapeutic or diagnostic agent into heart tissue of a patient. The method comprises introducing the distal end of a catheter as described in the preceding paragraph into the patient's heart. The injection needle is extended beyond the distal end of the tip section, and it is determined whether the injection needle has penetrated the heart tissue, preferably by measuring the impedance across the electrode mounted on the injection needle. If the injection needle has penetrated the tissue, the therapeutic or diagnostic agent is injected into the heart tissue with the injection needle. Otherwise, the physician can reposition the distal end of the catheter and again attempt to penetrate the heart tissue.

#### DESCRIPTION OF THE DRAWINGS

These and other features and advantages of the present invention will be better understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:

Figure 1 is a side plan view of one embodiment of the catheter of the present invention.

Figure 2a is a side cross-sectional view of the needle control handle where the needle is in a retracted position.

Figure 2b is a side cross-sectional view of the needle control handle where the needle is in an extended position.

Figure 3A is a side cross-sectional view of a tip section according to the invention having three lumens, showing the position of the electromagnetic mapping sensor and the injection needle.

Figure 3B is a side cross-sectional view of a tip section according to the invention showing a lead wire attached to the distal end of the injection needle.

Figure 3C is a side cross-sectional view of a tip section according to the invention showing an injection needle with a penetration-monitoring electrode mounted thereon.

Figure 3D is a close-up view of the penetration-monitoring electrode of Figure 3C.

Figure 4 is a side cross-sectional view of the tip section of Figure 3A showing the position of the electromagnetic mapping sensor and the puller wire.

Figure 5 is a side cross-sectional view of the catheter body, including the junction between the catheter body and the section.

Figure 6 is a transverse cross-sectional view of the tip section of Figure 3 along line 6-6 showing an embodiment having three lumens.

Figure 7 is a transverse cross-sectional view of the catheter body along line 7-7.

Figure 8 is a side cross-sectional view of the catheter handle according to the invention.

## DETAILED DESCRIPTION

In a preferred embodiment of the invention, there is provided a catheter for use for injection of a therapeutic or diagnostic agent into the heart. As shown in Figure 1, catheter **10** comprises an elongated catheter body **12** having proximal and distal ends, a tip section **14** at the distal end of the catheter body, a deflection control handle **16** at the proximal end of the catheter body, and a needle control handle **17** proximal the catheter body.

With reference to Figures 5 and 7, the catheter body **12** comprises a single, central or axial lumen **18**. The catheter body **12** is flexible, i.e., bendable, but substantially non-compressible along its length. The catheter body **12** may be of any suitable construction and made of any suitable material. A presently preferred construction comprises an outer wall **22** made of a polyurethane or nylon. The outer wall **22** comprises an imbedded braided mesh of stainless steel or the like to increase torsional stiffness of the catheter body **12** so that, when the control handle **16** is rotated, the tip section **14** of the catheter will rotate in a corresponding manner.

The outer diameter of the catheter body **12** is not critical, but is preferably no more than about 8 French. Likewise the thickness of the outer wall **22** is not critical. The inner surface of the outer wall **22** is lined with a stiffening tube **20**, which can be made of any suitable material, preferably polyimide. The stiffening tube, along with the braided outer wall **22**, provides improved torsional stability while at the same time minimizing the wall thickness of the catheter, thus maximizing the diameter of the single lumen. The outer diameter of the stiffening tube **20** is about the same as or slightly smaller than the inner diameter of the outer wall **22**. Polyimide tubing is presently preferred because it may be very thin walled while still providing very good stiffness. This maximizes the diameter of the central lumen **18** without sacrificing strength and stiffness. Polyimide material is typically not used for stiffening tubes because of its tendency to kink when bent. However, it has been found that, in combination with an outer wall **22** of polyurethane, nylon or other similar material, particularly having a stainless steel braided mesh, the tendency for the polyimide stiffening tube **20** to kink when bent is essentially eliminated with respect to the applications for which the catheter is used. If desired, the stiffening tube **20** can be eliminated.



As shown in Figures 3A, 4 and 6, the tip section **14** comprises a short section of tubing **19** having three lumens **30**, **32** and **34**. The tubing **19** is made of a suitable non-toxic material that is preferably more flexible than the catheter body **12**. A presently preferred material for the tubing **19** is braided polyurethane, i.e., polyurethane with an embedded mesh of braided stainless steel or the like. The outer diameter of the tip section **14**, like that of the catheter body **12**, is preferably no greater than about 8 French. The size of the lumens is not critical. In a particularly preferred embodiment, the tip section has an outer diameter of about 7 French (.092 inch) and the first lumen **30** and second lumen **32** are generally about the same size, having a diameter of about 0.022 inch, with the third lumen **34** having a slightly larger diameter of about 0.036 inch.

A preferred means for attaching the catheter body **12** to the tip section **14** is illustrated in Figure 5. The proximal end of the tip section **14** comprises an inner counter bore **24** that receives the outer surface of the polyimide stiffener **20**. The tip section **14** and catheter body **12** are attached by glue or the like.

The stiffening tube **20** is held in place relative to the outer wall **22** at the proximal end of the catheter body **12**. In preferred construction of the catheter body **12**, a force is applied to the proximal end of the stiffening tube **20** that causes the distal end of the stiffening tube to firmly push against the counter bore **24**. While under compression, a first glue joint is made between the stiffening tube **20** and the outer wall **22** by a fast drying glue, e.g. Super Glue®. Thereafter a second glue joint is formed between the proximal ends of the stiffening tube **20** and outer wall **22** using a slower drying but stronger glue, e.g., polyurethane. Any other suitable method of attaching the catheter body **12** to the tip section **14** can be used.

Extending through the single lumen **18** of the catheter body **12** are lead wires **40**, an injection needle **46**, a sensor cable **74**, and a compression coil **44** through which a puller wire **42** extends. A single lumen **18** catheter body is preferred over a multi-lumen body because it has been found that the single lumen **18** body permits better tip control when rotating the catheter **10**. The single lumen **18** permits the lead wires **40**, the injection needle **46**, the sensor cable **74**, and the puller wire **42** surrounded by the compression coil **44** to float freely within the catheter body. If such wires and cables were restricted within multiple lumens, they tend to build up energy when the handle **16** is rotated, resulting in the catheter body **12** having a tendency to rotate back if, for example, the handle is released, or if bent around a curve, to flip over, either for which are undesirable performance characteristics.

With reference to Figures 3A and 4, mounted at the distal end of the tip section **14** is a tip electrode **36**. Preferably the tip electrode **36** has a diameter about the same as the outer

diameter of the tubing **19**. The tip electrode **36** is connected to the tubing **19** by means of a plastic housing **21**, preferably made of polyetheretherketone (PEEK). The proximal end of the tip electrode **36** is notched circumferentially and fits inside the distal end of the plastic housing **21** and is bonded to the housing **21** by polyurethane glue or the like. The proximal end of the plastic housing **21** is bonded with polyurethane glue or the like to the distal end of the tubing **19** of the tip section **14**. Alternatively, the tip electrode **36** can be mounted directly to the distal end of the flexible tubing **19** of the tip section **14**, with the housing **21** eliminated.

Mounted on the distal end of the plastic housing **21** is a ring electrode **38**. The ring electrode **38** is slid over the plastic housing **21** and fixed in place by glue or the like. Alternatively, if the plastic housing **21** is eliminated, the ring electrode can be positioned over the flexible tubing **19** of the tip section **14**. If desired, additional ring electrodes may be used and can be positioned over the plastic housing **21** or over the flexible tubing **19** of the tip section **14**.

The tip electrode **36** and ring electrode **38** are each connected to a separate lead wire **40**. The lead wires **40** extend through the third lumen **34** of tip section **14**, the catheter body **12**, and the control handle **16**, and terminate at their proximal end in an input jack (not shown) that may be plugged into an appropriate monitoring system for measuring and displaying electrical activity (not shown) and/or a source of RF energy (not shown). If desired, the portion of the lead wires **40** extending through the catheter body **12**, control handle **16** and proximal end of the tip section **14** may be enclosed or bundled within a protective tube or sheath (not shown).

The lead wires **40** are attached to the tip electrode **36** and ring electrode **38** by any conventional technique. Connection of lead wire **40** to the tip electrode **36** is preferably accomplished by weld **43**, as shown in Figure 4.

A puller wire **42** is provided for deflection of the tip section **14**. The puller wire **42** is anchored at its proximal end to the control handle **16** and anchored at its distal end in the tip section **14**, as discussed in more detail below. The puller wire **42** is made of any suitable metal, such as stainless steel or Nitinol, and is preferably coated with Teflon® or the like. The coating imparts lubricity to the puller wire **42**. The puller wire **42** preferably has a diameter ranging from about 0.006 to about 0.010 inches.

As discussed above, a compression coil **44** is provided in surrounding relation to a portion of the puller wire **42**. The compression coil **44** extends from the proximal end of the catheter body **12** to the proximal end of the tip section **14**. The compression coil **44** is made of any suitable metal, preferably stainless steel. The compression coil **44** is tightly wound on itself to provide flexibility, i.e., bending, but to resist compression. The inner diameter of the compression

coil **44** is preferably slightly larger than the diameter of the puller wire **42**. For example, when the puller wire **42** has a diameter of about 0.007 inches, the compression coil **44** preferably has an inner diameter of about 0.008 inches. The Teflon® coating on the puller wire **42** allows it to slide freely within the compression coil **44**. Along most of its length, the outer surface of the compression coil **44** is covered by a flexible, non-conductive sheath **26** to prevent contact between the compression coil **44** and any of the lead wires **40**, injection needle **46** or sensor cable **74**. A non-conductive sheath **26** made of polyimide tubing is presently preferred.

In the depicted embodiment, the compression coil **44** is anchored at its proximal end to the proximal end of the stiffening tube **20** in the catheter body **12** by glue to form a glue joint **50** and at its distal end to the tip section **14** in the second lumen **32**, also forming a glue joint **50**. If a stiffening tube **20** is not used, the proximal end of the compression coil **44** can be glued directly to the outer wall **22** of the catheter body **12**. The glue may be applied by means of a syringe or the like through a hole made between the outer surface of the catheter body **12** and the single lumen. Alternatively, the distal end of the compression coil **44** can be anchored in the distal end of the catheter body **12**, for example, by gluing the compression coil to the stiffening tube **20** or the outer wall **22**, if a stiffening tube is not used.

The puller wire **42** extends out of the distal end of the compression coil **44** and into the second lumen **32** of the tip section **14**. The distal end of the puller wire **42** is anchored to the tip electrode **36** or to the side of the tip section **14** by any suitable method known in the art. Examples of suitable methods for anchoring the puller wire **42** in the tip section **14** are described in U.S. Patent Nos. 5,383,923 and 5,827,278, the disclosures of which are incorporated herein by reference. With reference to Figures 4 and 5, within the tip section **14**, and distal to the glue joint **50**, the turns of the compression coil **44** are expanded **49** longitudinally. The expanded turns **49** are both bendable and compressible and preferably extend for a length of about 0.5 inch. The puller wire **42** extends through the expanded turns **49** then into a plastic, preferably Teflon®, sheath **81**, which prevents the puller **42** from cutting into the wall of the tip section **14** when the tip section is deflected. If desired, the expanded turns **49** can be eliminated.

An extendable and retractable injection needle **46** is provided for injection of drugs and therapeutic and diagnostic agents into the heart tissue. The injection needle **46** extends from the needle control handle **17** through the catheter body **12**, through the first lumen **30** of the tip section **14** and through a passage **51** in the tip electrode **36**. As illustrated in Figure 3A, the injection needle **46** is preferably formed with a beveled edge **41** at the distal tip of the needle. The needle **46** is coaxially mounted within a protective tube **47**, preferably made of polyimide,

which serves to prevent the needle from buckling and also serves to electrically insulate the needle from the tip electrode 36. The protective tube 47 additionally serves to provide a fluid-tight seal surrounding the injection needle 46 to prevent body fluids from entering the distal end of the catheter. Preferably the protective tube 47 is provided along the entire length of the injection needle 46, although it can cover only the distal portion of the injection needle if desired.

Figure 3A depicts the injection needle 46 extending beyond the distal end of the tip electrode 36, as it would be positioned in order to infuse diagnostic or therapeutic fluid into the heart tissue. The catheter is designed to permit the distal end of the injection needle 46 to be withdrawn into the tip electrode 36 during the period of time that the catheter is inserted through the vasculature of the body and also during the period of time in which the catheter is removed from the body to avoid injury. Alternatively, the tip section 14 can be provided without a tip electrode 36, in which case the distal end of the injection needle 46 could be retracted into the first lumen 30 of the tip section 14. In either embodiment, the injection needle 46 is extendable and retractable beyond the distal end of the catheter. If desired, the catheter can include a needle stop mechanism for limiting the distance that the needle extends beyond the distal end of the tip section 14. Such a mechanism is described in copending U.S. Patent Application Serial No. 09/563,769, entitled "Injection Catheter with Needle Stop" to Dean Ponzi, the entire disclosure of which is incorporated herein by reference.

The injection needle 46 is made from one or more straight pieces of small diameter tubing having an outer diameter that allows the tubing to fit within the catheter. Preferably the injection needle 46 has an inner diameter ranging from about 0.007 inch to about 0.011 inch, and an outer diameter ranging from about 0.012 inch to about 0.016 inch. Preferably the injection needle 46 has a total length ranging from about 65 to about 85 inches, more preferably about 75 inches, although the length can vary as desired depending on the length of the catheter in which it is used and the application for which it is to be used.

In one embodiment, the injection needle 46 is formed of Nitinol or other conductive material. Alternatively, a portion of the needle is formed of plastic with the distal portion of the needle being formed of a conductive metal, such as Nitinol. The needle, whether all metal or part metal and part plastic, preferably has straight position memory so that when it is bent to a small radius, its natural tendency is to spring back to the straight position. This property is particularly important for the distal region of the injection needle (i.e., the portion of the needle within the tip section 14), because when the tip section is deflected, the needle will deflect with the tip section. When the tip section is then straightened from its deflected position, the memory of the

distal region of the needle pushes the tip section back towards the straight position to the same axis as the catheter body. If desired, at least a portion of the tubing, such as the portion that forms the distal region of the needle, is provided with a lubricious coating, such as Teflon® or silicone, preferably having a thickness ranging from about 0.0003 inch to about 0.002 inch. In another alternative embodiment, a biocompatible lubricant, such as mineral oil is injected around the needle once assembled.

If desired, the distal end of the injection needle **46** is provide with one or more fluid openings (not shown) along its length. The fluid openings can be of any suitable shape, such as round, oval, or rectangular. The fluid openings can be provided only on one side of the needle **46**, or about the circumference of the needle. The fluid openings enhance the ability of the drug or other agent passing through the needle to weep into the injection site and be more evenly distributed, allowing for better absorption of the agent by the heart tissue.

A needle electrode lead wire **39** is electrically connected to the injection needle **46** to permit the injection needle to also function as an electrode. In one embodiment, the injection needle **46** comprises metal along its entire length, and the needle electrode lead wire **39** is attached near the proximal end of the injection needle within the deflection control handle **16**, as described in more detail below.

In an alternative embodiment, as shown in Figure 3B, the needle electrode lead wire **39** is electrically connected near the distal end of the injection needle **46** within the tip section **14**. In this embodiment, the needle electrode lead wire **39** extends within the protective tube **47** along with the injection needle **46**, and the distal end of the needle electrode lead wire is soldered, welded or otherwise electrically attached to the injection needle within the protective tube. In this embodiment, it is only necessary that the distal end of the injection needle **46**, i.e., the end to which the needle electrode lead wire **39** is attached, be made of metal, and the remainder of the injection needle can be made of metal or plastic, as desired.

Preferably in this embodiment the needle electrode lead wire **39** comprises a pair of wires, a first wire of a high conductivity material (e.g., copper) and a second wire of a high strength material different from the first material (e.g., constantan) non-conductively bonded to the first wire. This pair of wires acts as a thermocouple in addition to an electrode lead wire. More details on such an arrangement are disclosed in U.S. Patent No. 5,893,885, the disclosure of which is incorporated herein by reference. If desired, the portion of the injection needle **46** to which the needle electrode lead wire **39** is attached can be covered with a thin coating of Teflon or the like (not shown) to enhance the ability of the injection needle to slide within the protective

tube **47** and to prevent the needle electrode lead wire from getting stuck or caught on the protective tube as the injection needle is being slid in and out of the tip section **14**.

The injection needle **46** can be used to infuse therapeutic agents, diagnostic agents and the like. Particularly preferred agents include angiogenesis activators, angiogenesis inhibitors, and antiarrhythmic drugs. Examples of angiogenesis activators include vascular endothelial growth factor, vascular endothelial growth factor receptor, neuropilin-1, angiopoietins, such as Ang1, tyrosine kinases (Tie), such as Tie2, transforming growth factor- $\beta$ 1, transforming growth factor- $\beta$  receptors, endoglin, chemokines, hepatocyte growth factor, monocyte chemoattractant protein-1 integrins, such as  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ ,  $\alpha_5\beta_1$ , VE-cadherin, platelet-endothelial cell-adhesion molecule, ephrins, plasminogen activators, matrix metalloproteinases, and cyclo-oxygenase-2. Examples of angiogenesis inhibitors include vascular endothelial growth factor receptor-1, neuropilin-1, angiopoietins, such as Ang2, angiostatin and related plasminogen kringle, endostatin (collagen XVIII fragment), vasostatin, calreticulin, platelet factor-4, matrix metalloproteinase inhibitors, prothrombin kringle-2, antithrombin III fragment, maspin, canstatin, proliferin-related protein, and restin. Examples of antiarrhythmic drugs include sodium channel blockers, potassium channel blockers, membrane-stabilizing agents, and  $\alpha$ -adrenoceptor blockers,  $\beta$ -adrenoceptor blockers and calcium channel blockers.

In use, the injection needle **46** can function as a mapping electrode and/or as an ablation electrode. For example, the injection needle **46** can be used to map the electrical activity of the heart, alone or in combination with the tip electrode **36** and/or ring electrodes **38**, prior to injection of a therapeutic or diagnostic agent into the heart tissue. Using this method, the physician can more precisely position the injection needle at a desired location. The invention is also contemplated for epicardial applications.

Alternatively, the injection needle **46** can be used to ablate heart tissue before, during or after injection of the therapeutic or diagnostic agent, as desired. Ablation often enhances the effectiveness of a therapeutic agent. Specifically, creating an injury that causes an inflammation response, which results in having white blood cells coming to injury site and fighting the inflammation, makes the target site susceptible to an agent.

Additionally, the injection needle **46** can be used to determine the extent of needle penetration in the heart tissue. For this methodology, it is preferred that the needle electrode lead wire **39** be attached to the proximal end of the injection needle **46**. During a procedure, the physician monitors the impedance of the injection needle **46** relative to the tip electrode **36** (or a ring electrode **38**, if a tip electrode is not used). If the distal end of the injection needle **46** is

within the heart tissue, the difference in impedance will be relatively high (e.g., around 500 to 600  $\Omega$ ). Accordingly, the physician can then proceed to inject the therapeutic or diagnostic agent. In contrast, if the distal end of the injection needle **46** for some reason has not penetrated the heart tissue, but is only in contact with blood, the difference in impedance will be relatively low (e.g., around 100 to 150  $\Omega$ ). This information indicates to the physician that he or she should reattempt to penetrate the heart tissue with the needle before injecting the agent.

In another alternative embodiment, as shown in Figures 3C and 3D, a penetration-monitoring electrode **48** is mounted on the injection needle **46** for monitoring whether and to what extent the injection needle has penetrated the tissue. In the depicted embodiment, the penetration-monitoring electrode **48** is electrically isolated from the injection needle **46** by a thin non-conductive (preferably Teflon) covering **59** on the needle. The penetration-monitoring electrode **48** can be mounted by any other suitable non-conductive method, such as with polyurethane glue. A lead wire **61** is electrically connected to the penetration-monitoring electrode **48** by any suitable means, such as weld, solder, or the like. The penetration-monitoring electrode **48** is positioned at a position along the length of the injection needle **46** that generally corresponds to the desired depth that the needle penetrate the heart tissue. In this embodiment, the injection needle **46** may optionally also act as a separate electrode, i.e., have an electrode lead wire **39** electrically connected thereto.

In use, once the physician believes he or she has penetrated the tissue with the injection needle **46**, he monitors the impedance of the penetration-monitoring electrode **48** relative to the tip electrode **36** (or a ring electrode **38**). If the penetration-monitoring electrode **48** is in contact with the heart tissue, the difference in impedance will be relatively high, and if the penetration-monitoring electrode is not in contact with the tissue, but only in contact with blood, the difference in impedance will be relatively low. Similar to the method described above, this information indicates to the physician whether the injection needle has penetrated the heart tissue at the desired depth.

Additionally, a location sensor, preferably an electromagnetic location sensor **72**, is contained within the distal end of the tip section **14**. The electromagnetic sensor **72** is connected to the electromagnetic sensor cable **74**, which extends through the third lumen **34** of the tip section **14**, through the catheter body **12**, and into the deflection control handle **16**. The electromagnetic sensor cable **74** comprises multiple wires encased within a plastic sheath. In the deflection control handle **16**, the wires of the sensor cable **74** are connected to a circuit board **64**. The circuit board **64** amplifies the signal received from the electromagnetic sensor and transmits

it to a computer in a form understandable by the computer. Also, because the catheter is designed for single use only, the circuit board contains an EPROM chip which shuts down the circuit board after the catheter has been used. This prevents the catheter, or at least the electromagnetic sensor, from being used twice. Suitable electromagnetic sensors for use in connection with the present invention are described, for example, in U.S. Patent No. 4,391,199 and U.S. Patent Application No. 09/160,063, entitled "Miniaturized Position Sensor," the disclosures of which are incorporated herein by reference. A preferred electromagnetic mapping sensor **72** is manufactured by Biosense Webster, Inc. and marketed under the trade designation NOGA. To use the electromagnetic sensor **72**, the patient is placed in a magnetic field generated, for example, by situating under the patient a pad containing coils for generating a magnetic field. A reference electromagnetic sensor is fixed relative to the patient, e.g., taped to the patient's back, and the injection catheter containing a second electromagnetic sensor is advanced into the patient's heart. Each sensor comprises three small coils which in the magnetic field generate weak electrical signals indicative of their position in the magnetic field. Signals generated by both the fixed reference sensor and the second sensor in the heart are amplified and transmitted to a computer which analyzes the signals and then displays the signals on a monitor. By this method, the precise location of the sensor in the catheter relative to the reference sensor can be ascertained and visually displayed. The sensor can also detect displacement of the catheter that is caused by contraction of the heart muscle.

Using this technology, the physician can visually map a heart chamber. This mapping is done by advancing the catheter tip into a heart chamber until contact is made with the heart wall. This position is recorded and saved. The catheter tip is then moved to another position in contact with the heart wall and again the position is recorded and saved.

The electromagnetic mapping sensor **72** can be used alone or, more preferably, in combination with the needle electrode **46**, tip electrode **36** and/or ring electrode **38**. By combining the electromagnetic sensor **72** and one or more of the electrodes **46**, **36** and/or **38**, a physician can simultaneously map the contours or shape of the heart chamber, the electrical activity of the heart, and the extent of displacement of the catheter and hence identify the presence and location of the ischemic tissue. Specifically, the electromagnetic mapping sensor **72** is used to monitor the precise location of the tip electrode in the heart and the extent of catheter displacement. The needle electrode **46**, tip electrode **36** and ring electrode **38** can be used to monitor the strength of the electrical signals at that location. Healthy heart tissue is identified by strong electrical signals in combination with strong displacement. Dead or diseased



heart tissue is identified by weak electrical signals in combination with dysfunctional displacement, i.e., displacement in a direction opposite that of healthy tissue. Ischemic, or hibernating or stunned, heart tissue is identified by strong electrical signals in combination with impaired displacement. Hence, the combination of the electromagnetic mapping sensor **72** and needle, tip and/or ring electrodes **46**, **36** and **38** is used as a diagnostic catheter to determine whether and where to infuse a drug into the wall of the heart. Once the presence and location of ischemic tissue has been identified, the tip section **14** of the catheter can be deflected so that the injection needle **46** is generally normal, i.e., at a right angle, to the ischemic tissue. The injection needle **46** may then be extended out of the distal end of the tip electrode **36** (if not already extended for mapping purposes) and into the wall of the heart.

It is understood that, while it is preferred to include both electrophysiology electrodes and an electromagnetic sensor in the catheter tip, it is not necessary to include both. For example, an injection catheter having an electromagnetic sensor but no electrophysiology electrodes may be used in combination with a separate mapping catheter system. A preferred mapping system includes a catheter comprising multiple electrodes and an electromagnetic sensor, such as the NOGA-STAR catheter marketed by Biosense Webster, Inc., and means for monitoring and displaying the signals received from the electrodes and electromagnetic sensor, such as the Biosense-NOGA system, also marketed by Biosense Webster, Inc.

The electrode lead wires **40** and electromagnetic sensor cable **74** must be allowed some longitudinal movement within the catheter body so that they do not break when the tip section **14** is deflected. To provide for such lengthwise movement, there is provided a tunnel through the glue joint **50**, which fixes the proximal end of the compression coil **44** inside the catheter body **12**. The tunnel is formed by a transfer tube **27**, preferably made of a short segment of polyimide tubing. Preferably the transfer tube **27** is approximately 60 mm long and has an outer diameter of about .021 inch and an inner diameter of about .019 inch.

Longitudinal movement of the puller wire **42** relative to the catheter body **12**, which results in deflection of the tip section **14**, is accomplished by suitable manipulation of the deflection control handle **16**. As shown in Figure 8, the deflection control handle **16** comprises a handle housing **52** and a piston **54** having an axial passage **55** and a thumb control **56**. The proximal end of the catheter body **12** is connected to the piston **54** by means of a shrink sleeve **28**.

The injection needle **46** within the protective tube **47**, the puller wire **42**, the lead wires **40** and the electromagnetic sensor cable **74** extend through the axial passage **55** of the piston **54**. The

puller wire 42 is anchored to an anchor pin 57 located proximal to the piston 54. The lead wires 40 and electromagnetic sensor cable 74 extend through a first tunnel 58 in the handle housing 52, located near a side of the deflection control handle 16. The electromagnetic sensor cable 74 connects to the circuit board 64 in the proximal end of the deflection control handle 16. Wires 80 connect the circuit board 64 to a computer and imaging monitor (not shown).

The injection needle 46 and protective tube 47 extend through a guide tube 66, preferably made of polyurethane, and are afforded longitudinal movement therein. The guide tube 66 is anchored to the piston 54, preferably by a glue joint 53. This design affords the injection needle 46 and protective tube 47 longitudinal movement within the deflection control handle 16 so that the needle does not break when the piston 54 is adjusted to manipulate the catheter body 12 relative to the handle housing 52 and the puller wire 42. Within the piston 54, the electromagnetic sensor cable 74 and lead wires 40 are situated within a first transfer tube 27a, and the puller wire 42 is situated within a second transfer tube 27b to allow longitudinal movement of the wires and cable near the glue joint 53.

The injection needle 46, protective tube 47 and guide tube 66 extend through a second tunnel 60 in the handle housing 52 situated near the side of the control handle 16 opposite the anchor pin 57. To avoid undesirable bending of the injection needle 46, a space 62 is provided in the handle housing 52 between the proximal end of the piston 54 and the distal end of the second tunnel 60. Preferably the space 62 has a length of at least about 0.50 inch and more preferably about from about 0.60 inch to about 0.90 inch.

In the proximal end of the deflection control handle 16, the injection needle 46, protective tube 47 and polyurethane guide tube 66 extend through a second larger plastic guide tube 68, preferably made of Teflon®, which affords the guide tube 66, injection needle 46, and protective tube 47 longitudinal slidable movement. The second guide tube 68 is anchored to the inside of the handle housing 52 by glue or the like and extends proximally beyond the control handle 16. The second guide tube 68 protects the injection needle 46 both from contact with the circuit board 64 and from any sharp bends as the guide tube 66, needle 46, and protective tube 47 emerge from the deflection control handle 16.

In the depicted embodiment, the needle electrode lead wire 39 is electrically connected to the injection needle 46 within the deflection control handle 16. Specifically, a hole 67 is provided in the guide tube 66 and protective tube 47. The needle electrode lead wire 39 passes through the hole 67 and is attached to the injection needle 46 by weld, solder or the like within the guide tube 66 and protective tube 47. Alternatively, for the embodiment depicted in

Figure 3B, where the needle electrode lead wire **39** is connected to the distal end of the injection needle **46**, the needle electrode lead wire passes through the hole **67** and extends along the length of the injection needle **46** like within the guide tube **66** and protective tube **47**.

Extension and retraction of the injection needle **46** out the distal end of the tip electrode **36** is accomplished by the needle control handle **17**. As illustrated in Figures 2a and 2b, the needle control handle **17** comprises a generally cylindrical outer body **80** having proximal and distal ends, a piston chamber **82** extending a part of the way therethrough, and a needle passage **83** extending a part of the way therethrough. The piston chamber **82** extends from the proximal end of the needle control handle part way into the body **80**, but does not extend out the distal end of the body. The needle passage **83**, which has a diameter less than that of the piston chamber **82**, extends from the proximal end of the piston chamber to the proximal end of the outer body **80**.

A piston **84**, having proximal and distal ends, is slidably mounted within the piston chamber **82**. The piston **84** has an axial passage **85** through which the injection needle **46** extends, as described in more detail below. A Luer connector **86** is mounted in the distal end of the outer body **80**. A compression spring **88** is mounted within the piston chamber **82** between the distal end of the piston **84** and the outer body **80**.

The proximal end of the injection needle **46** is mounted to the Luer connector **86** by means of a first rigid tube **90**, preferably made of stainless steel, which has a proximal end fitted into the Luer connector. This arrangement fixedly attaches the injection needle **46** to the piston **84** so that it moves longitudinally with the piston. The first rigid tube **90** is also fixedly attached to the piston **84** and moves longitudinally with the piston. The injection needle **46** and first rigid tube **90** extend through the axial passage **85** of the piston **84**. Within the axial passage **85**, a second rigid tube **91**, preferably made of stainless steel, has a proximal end mounted coaxially within the distal end of the first rigid tube **90**. The proximal end of the second rigid tube **91** is mounted within the protective tube **47**, which has its proximal end inside the axial passage **85**, and the distal end of the second rigid tube is attached, directly or indirectly, to the outer body **80**. The guide tube **66**, through which the protective tube **47** and injection needle **46** extend, as discussed above, is fixedly attached to the outer body **80** by means of a shrink sleeve **92**, as is generally known in the art.

In use, force is applied to the piston **84** to cause distal movement of the piston relative to the outer body **80**, which compresses the compression spring **88**. This movement causes the injection needle **46** to correspondingly move distally relative to the outer body, guide tube **66**,

protective tube **47** and catheter body **12**, so that the distal end of the injection needle extends outside the distal end of the tip electrode **36**. Upon distal movement of the piston **84**, the first rigid tube **91** moves distally over the second rigid tube **91** to prevent the injection needle **46** from buckling within the axial passage **85**. When the force is removed from the piston **54**, the compression spring **88** pushes the piston **84** proximally to its original position, thus causing the distal end of the injection needle **46** to retract back into the tip electrode **36**.

The piston **84** further comprises a longitudinal slot **100** extending along a portion of its outer edge. A set screw **102** extends through a hole in the outer body **80** and into the longitudinal slot **100**. This design limits the distance that the piston **84** can be slid proximally out of the piston chamber **82**, and, if desired, the distance that the piston can be slid distally to extend the injection needle **46**. When the distal end of the injection needle **46** is in the retracted position, preferably the set screw **102** is at or near the distal end of the longitudinal slot **100**.

The proximal end of the piston **84** has a threaded outer surface **104**. A circular thumb control **106** is mounted on the proximal end of the piston **84**. The thumb control **106** has a threaded inner surface **108** that interacts with the threaded outer surface **104** of the piston **84**. The thumb control **106** acts as a stop, limiting the distance that the piston **84** can be pushed into the piston chamber **82**, and thus the distance that the injection needle **46** can be extended out the distal end of the catheter. The threaded surfaces of the thumb control **106** and piston **84** allow the thumb control to be moved closer or farther from the proximal end of the outer body **80** so that the extension distance of the injection needle can be controlled by the physician. A tension screw **110** is provided in the thumb control **106** to control the tension between the thumb control and piston **84**. As would be recognized by one skilled in the art, the thumb control **106** can be replaced by any other mechanism that can act as a stop for limiting the distance that the piston **84** extends into the piston chamber **82**, and it is not necessary, although it is preferred, that the stop be adjustable relative to the piston.

In another preferred embodiment constructed in accordance with the present invention, two or more puller wires (not shown) are provided to enhance the ability to manipulate the tip section. In such an embodiment, a second puller wire and a surrounding second compression coil extend through the catheter body and into separate off-axis lumens in the tip section. The lumens of the tip section receiving the puller wires may be in adjacent quadrants. The first puller wire is preferably anchored proximal to the anchor location of the second puller wire. The second puller wire may be anchored to the tip electrode or may be anchored to the wall of the tip section adjacent the distal end of tip section.

The distance between the distal end of the compression coils and the anchor sites of each puller wire in the tip section determines the curvature of the tip section **14** in the direction of the puller wires. For example, an arrangement wherein the two puller wires are anchored at different distances from the distal ends of the compression coils allows a long reach curve in a first plane and a short reach curve in a plane 90° from the first, i.e., a first curve in one plane generally along the axis of the tip section before it is deflected and a second curve distal to the first curve in a plane transverse, and preferably normal to the first plane. The high torque characteristic of the catheter tip section **12** reduces the tendency for the deflection in one direction to deform the deflection in the other direction. Suitable deflection control handles for use with such a catheter are described in U.S. Patent No. 6,123,699, entitled "Omni-Directional Steerable Catheter", and U.S. Patent Application Nos. 09/130,359, filed August 7, 1998, entitled "Bi-Directional Control Handle for Steerable Catheter", 09/143,426, filed August 28, 1998, entitled "Bidirectional Steerable Catheter with Bidirectional Control Handle", and 09/546,310, filed April 10, 2000, entitled "Single Gear Drive Bidirectional Control Handle for Steerable Catheter", the disclosures of which are incorporated herein by reference.

As an alternative to the above described embodiment, two puller wires may extend into diametrically opposed off-axis lumens in the tip section. In such an embodiment, each of the puller wires may be anchored at the same location along the length of the tip section, in which case the curvatures of the tip section in opposing directions are the same and the tip section can be made to deflect in either direction without rotation of the catheter body.

The preceding description has been presented with reference to presently preferred embodiments of the invention. Workers skilled in the art and technology to which this invention pertains will appreciate that alterations and changes in the described structure may be practiced without meaningful departing from the principal, spirit and scope of this invention.

Accordingly, the foregoing description should not be read as pertaining only to the precise structures described and illustrated in the accompanying drawings, but rather should be read consistent with and as support to the following claims which are to have their fullest and fair scope.

WHAT IS CLAIMED IS:

1. An injection catheter comprising:
  - a catheter body comprising a flexible tubing having proximal and distal ends and at least one lumen therethrough;
  - a tip section comprising a flexible tubing having proximal and distal ends, wherein the proximal end of the tip section is mounted at the distal end of the catheter body;
  - a needle control handle at the proximal end of the catheter body;
  - an injection needle extending through the tip section, catheter body, and needle control handle and having a proximal end attached to the needle control handle and a distal end within the tip section, wherein the injection needle is longitudinally slidable within the tip section so that its distal end can extend beyond the distal end of the tip section upon suitable manipulation of the needle control handle; and
  - an electrode lead wire having a first end electrically connected to the injection needle and a second end electrically connected to a suitable monitoring apparatus or to a source of ablation energy.
2. An injection catheter according to claim 1, wherein the first end of the electrode lead wire is connected near the proximal end of the injection needle.
3. An injection catheter according to claim 1, wherein the first end of the electrode lead wire is connected near the distal end of the injection needle.
4. An injection catheter according to claim 3, wherein the electrode lead wire comprises a pair of wires including a copper wire and a constantan wire that can act as a thermocouple.
5. An injection catheter according to claim 1, further comprising a protective tube in surrounding relation to at least a portion of the injection needle.
6. An injection catheter according to claim 5, wherein the protective tube surrounds the injection needle along substantially the entire length of the needle.

7. An injection catheter according to claim 1, further comprising at least one additional electrode mounted on the tip section.

8. An injection catheter according to claim 1, further comprising a tip electrode mounted on the distal end of tip section.

9. An injection catheter comprising:  
a catheter body comprising a flexible tubing having proximal and distal ends and at least one lumen therethrough;  
a tip section comprising a flexible tubing having proximal and distal ends, wherein the proximal end of the tip section is mounted at the distal end of the catheter body;  
a needle control handle at the proximal end of the catheter body;  
an injection needle extending through the tip section, catheter body, and needle control handle and having a proximal end attached to the needle control handle and a distal end within the tip section, wherein the injection needle is longitudinally slidable within the tip section so that its distal end can extend beyond the distal end of the tip section upon suitable manipulation of the needle control handle;  
an electrode mounted on the injection needle near the distal end of the injection needle and electrically isolated from the injection needle;  
an electrode lead wire having a first end electrically connected to the electrode and a second end electrically connected to a suitable monitoring apparatus or to a source of ablation energy.

10. An injection catheter according to claim 9, wherein the electrode is in the form of a ring mounted in surrounding relation to the injection needle.

11. An injection catheter according to claim 9, further comprising an electrode lead wire having a first end electrically connected to the injection needle and a second end electrically connected to a suitable monitoring apparatus or to a source of ablation energy.

12. A method for introducing a therapeutic or diagnostic agent into heart tissue of a patient comprising:

introducing the distal end of a catheter according to claim 1 into the patient's heart;

extending the injection needle beyond the distal end of the tip section;  
determining whether the injection needle has penetrated the heart tissue; and  
injecting a therapeutic or diagnostic agent into the heart tissue with the injection needle.

13. A method according to claim 12, wherein the determining step comprises measuring the impedance across the distal end of the injection needle.

14. A method according to claim 12, wherein the catheter further comprises at least one additional electrode at or near the distal end of the tip section.

15. A method according to claim 14, wherein the determining step comprises comparing the impedance across the distal end of the injection needle to the impedance across the additional electrode.

16. A method according to claim 12, wherein the therapeutic or diagnostic agent is selected from the group consisting of angiogenesis activators, angiogenesis inhibitors, and antiarrhythmic drugs.

17. A method for introducing a therapeutic or diagnostic agent into heart tissue of a patient comprising:

introducing the distal end of a catheter according to claim 9 into the patient's heart;  
extending the injection needle beyond the distal end of the tip section;  
determining whether the injection needle has penetrated the heart tissue; and  
injecting a therapeutic or diagnostic agent into the heart tissue with the injection needle.

18. A method according to claim 17, wherein the determining step comprises measuring the impedance across the electrode mounted on the injection needle.

19. A method according to claim 17, wherein the catheter further comprises at least one additional electrode at or near the distal end of the tip section.



37646/KMO/W112

20. A method according to claim 19, wherein the determining step comprises comparing the impedance across the electrode mounted on the injection needle to the impedance across the additional electrode.

# INJECTION CATHETER WITH NEEDLE ELECTRODE

## ABSTRACT

An injection catheter for infusing therapeutic and diagnostic agents into the heart is provided. The injection catheter comprises a catheter body comprising a flexible tubing having proximal and distal ends and at least one lumen therethrough. A tip section comprising a flexible tubing having proximal and distal ends is mounted at the distal end of the catheter body. A needle control handle is provided at the proximal end of the catheter body. An injection needle extends through the tip section, catheter body, and needle control handle and has a proximal end attached to the needle control handle and a distal end within the tip section. The injection needle is longitudinally slidable within the tip section so that its distal end can extend beyond the distal end of the tip section upon suitable manipulation of the needle control handle. The catheter further comprises an electrode lead wire having a first end electrically connected to the injection needle and a second end electrically connected to a suitable monitoring apparatus or to a source of ablation energy. The injection needle can thus be used for mapping or ablation in addition to introducing therapeutic and diagnostic agents into the heart.

KMO/nml

NML PAS260882 1-\*-11/13/00 3 47 PM

**FIG. 1**




FIG. 2a




FIG. 2b




FIG. 3A





FIG. 3B







**FIG. 3D**








FIG. 6





FIG. 7





**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATIONS**

PATENT

Docket No. : 37646/KMO/W112

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **INJECTION CATHETER WITH NEEDLE ELECTRODE**, the specification of which is attached hereto unless the following is checked:

\_\_\_ was filed on \_\_\_ as United States Application Number or PCT International Application Number \_\_\_ and was amended on \_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of the foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

<u>Application Number</u>	<u>Country</u>	<u>Filing Date (day/month/year)</u>	<u>Priority Claimed</u>
---------------------------	----------------	-------------------------------------	-------------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u>Application Number</u>	<u>Filing Date</u>
60/088,019	June 4, 1998
60/088,984	June 11, 1998

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u>Application Number</u>	<u>Filing Date</u>	<u>Patented/Pending/Abandoned</u>
09/280,202	March 29, 1999	Pending

**POWER OF ATTORNEY:** I hereby appoint the following attorneys and agents of the law firm CHRISTIE, PARKER & HALE, LLP to prosecute this application and any international application under the Patent Cooperation Treaty based on it and to transact all business in the U.S. Patent and Trademark Office connected with either of them in accordance with instructions from the assignee of the entire interest in this application;

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATIONS**

**Docket No. 37646/KMO/W112**

or from the first or sole inventor named below in the event the application is not assigned; or from \_\_ in the event the power granted herein is for an application filed on behalf of a foreign attorney or agent.

R. W. Johnston	(17,968)	Gregory S. Lampert	(35,581)	Cynthia A. Bonner	(44,548)
D. Bruce Prout	(20,958)	Grant T. Langton	(39,739)	Jun-Young E. Jeon	(43,693)
Hayden A. Carney	(22,653)	Constantine Marantidis	(39,759)	Marc A. Karish	(44,816)
Richard J. Ward, Jr.	(24,187)	Daniel R. Kimbell	(34,849)	John F. O'Rourke	(38,985)
Russell R. Palmer, Jr.	(22,994)	Craig A. Gelfound	(41,032)	Richard J. Paciulan	(28,248)
LeRoy T. Rahn	(20,356)	Syed A. Hasan	(41,057)	Josephine E. Chang	(46,083)
Richard D. Seibel	(22,134)	Kathleen M. Olster	(42,052)	Frank L. Cire	(42,419)
Walter G. Maxwell	(25,355)	Daniel M. Cavanagh	(41,661)	Harold E. Wurst	(22,183)
William P. Christie	(29,371)	Molly A. Holman	(40,022)	Robert A. Green	(28,301)
David A. Dillard	(30,831)	Lucinda G. Auciello	(42,270)	Derrick W. Reed	(40,138)
Thomas J. Daly	(32,213)	Norman E. Carte	(30,455)	John W. Peck	(44,284)
Vincent G. Gioia	(19,959)	Joel A. Kauth	(41,886)	Stephen D. Burbach	(40,285)
Edward R. Schwartz	(31,135)	Patrick Y. Ikehara	(42,681)	David B. Sandelands, Jr.	(46,023)
John D. Carpenter	(34,133)	Mark Garscia	(31,953)	Heidi L. Eisenhut	(46,812)
David A. Plumley	(37,208)	Gary J. Nelson	(44,257)	Nicholas J. Pauley	(44,999)
Wesley W. Monroe	(39,778)	Raymond R. Tabandeh	(43,945)	Mark J. Marcelli	(36,593)

The authority under this Power of Attorney of each person named above shall automatically terminate and be revoked upon such person ceasing to be a member or associate of or of counsel to that law firm.

**DIRECT TELEPHONE CALLS TO : Kathleen M. Olster, 626/795-9900**

**SEND CORRESPONDENCE TO : CHRISTIE, PARKER & HALE, LLP  
P.O. Box 7068, Pasadena, CA 91109-7068**

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor Dean M. Ponzi	Inventor's signature	Date
Residence and Post Office Address 1424 East Leadora Avenue, Glendora, California 91741		Citizenship U.S.A.

Full name of second joint inventor Asher Holzer	Inventor's signature	Date
Residence and Post Office Address 22 Shlomzion Street, Haifa 34406, Israel		Citizenship Israel

Full name of third joint inventor Shlomo Ben-Haim	Inventor's signature	Date
Residence and Post Office Address 101 Yeffe Nof Street, Haifa 34641, Israel		Citizenship Israel

KMO:nml  
NML PAS285116 1\*-11/13/00 10 12 AM